Charting is for gamblers. Period. Name me one chart that has worked on a biotech. Hogwash. Biotech is all about the science and the people running the company. Charts don't matter. EXEL has a drug that has an "unexplained" bone met thing. That's it for now. More importantly, it seems the people running the company are not right for the job. Also, the company has a huge debt load and will need more money again (more shares to offer). Plug that in the "charts" and see what you come up with.